NCT05553834
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 12 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 4, 2026 Show 4 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 16 words
- Secondary endpoints revised (3)
- Publications: details revised at 1 of 1 entry
- Minor Study completion pushed from Mar 1, 2026 to Nov 1, 2026v14
- Minor Primary completion date changed from estimate of Jan 1, 2026 to Sep 16, 2025
- Study completion date: Jan 1, 2027 to Mar 1, 2026
- Notable Primary completion date: Jan 1, 2027 to Jan 1, 2026
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: Jan 1, 2029 to Jan 1, 2027
- Site details revised at 2 of 2 sites
- Minor Study sites: 1 to 2v9
Show 6 earlier versionsHide 6 earlier versions
- Notable Enrollment target: 25 to 60v8
- Notable Trial status: Suspended to Recruiting
- Site details revised
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Accrual suspended to perform the interim safety analysis after 10th patient is treated on study.
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Apr 1, 2023 to May 16, 2023
- Notable Start date: Jan 1, 2023 to Apr 1, 2023
- Primary completion date: Oct 1, 2026 to Jan 1, 2027
- Study completion date: Oct 1, 2028 to Jan 1, 2029
- Notable Start date: Oct 1, 2022 to Jan 1, 2023v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 Criteria
Timeframe: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks per RECIST 1.1
Secondary (3)
Number of Participants Who Experienced an Adverse Event
Progression Free Survival (PFS) Per RECIST 1.1. Criteria
Overall Survival (OS)
Arms and interventions
Alirocumab and CemiplimabExperimental
Combination of anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab
Combination products: Alirocumab and Cemiplimab
Sites
2 sites in 1 country